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Abstract
Background: Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but
may be different for mirabegron, a b3-adrenoceptor agonist with a different adverse event
profile.
Objective: To compare persistence and adherence with mirabegron versus tolterodine ex-
tended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period.
Design, setting, and participants: Retrospective, longitudinal, observational study of anon-
ymised data from the UK Clinical Practice Research Datalink GOLD database. Eligibility: age
18 yr, 1 prescription for target OAB drug (between May 1, 2013 and June 29, 2014), and 12-
mo continuous enrolment before and after the index prescription date.
Interventions: Mirabegron, darifenacin, fesoterodine, ﬂavoxate, oxybutynin ER or immediate-
release (IR), propiverine, solifenacin, tolterodine ER or IR, and trospium chloride.
Outcome measurements and statistical analysis: The primary endpoint was persistence (time
to discontinuation). Secondary endpoints included 12-mo persistence rates and adherence
(assessed using medication possession ratio, MPR). Cox proportional-hazards regression
models and logistic regression models adjusted for potential confounding factors were used
to compare cohorts. Analyses were repeated after 1:1 matching.
Results and limitations: The study population included 21 996 eligible patients. In the un-
matched analysis, the median time-to-discontinuation was signiﬁcantly longer for mirabegron
(169 d, interquartile range [IQR] 41–not reached) compared to tolterodine ER (56 d, IQR 28–
254; adjusted hazard ratio [HR] 1.55, 95% conﬁdence interval 1.41–1.71; p < 0.0001) and other
antimuscarinics (range 30–78 d; adjusted HR range 1.24–2.26, p < 0.0001 for all comparisons).
The 12-mo persistence rates and MPR were also signiﬁcantly greater with mirabegron than
with all the antimuscarinics. Limitations include the retrospective design, use of prescription
records to estimate outcomes, and inability to capture reasons for discontinuation.
Conclusions: Persistence and adherence were statistically signiﬁcantly greater with mirabe-
gron than with tolterodine ER and other antimuscarinics prescribed for OAB in the UK.
Patient summary: This study assessed persistence and adherence (or compliance) with
medications prescribed for OAB in a large UK population. We found that patients prescribed
mirabegron remained on treatment for longer and showed greater adherence than those
prescribed traditional antimuscarinics.
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Overactive bladder (OAB) is a complex of lower urinary tract
storage symptoms characterised by urgency, with or
without urgency incontinence, and often accompanied by
frequency and nocturia in the absence of proven infection or
other pathology [1]. The condition is common, affecting an
estimated 12% of adults [2].
In the UK, pharmacotherapy is used to manage OAB
symptoms if lifestyle, behavioural, and conservative measures
fail [3,4]. Antimuscarinics are the mainstay of pharmacother-
apy for OAB. However, systemic blockade of muscarinic
receptors leads to common, bothersome class-related adverse
events such as dry mouth, constipation, and headache
[5]. Mirabegron, a selective b3-adrenoceptor agonist, is an
alternative treatment option with established efficacy in
patients with OAB [6–8]. Overall rates of treatment-emergent
adverse events for mirabegron are similar to those observed
for antimuscarinics [9], but the risk of dry mouth and
constipation is significantly lower for mirabegron [10].
Persistence (time from initiation to discontinuation of
therapy [11]) and adherence (extent to which a patient acts
in accordance with the prescribed interval and dose of a
dosing regimen [11]) with oral antimuscarinics are recog-
nised as among the lowest for medications used for
common chronic conditions [12] and fall rapidly after
treatment initiation [13]. Depending on the antimuscarinic
prescribed, 65–86% of patients discontinue therapy after
1 yr [14]. Real-world data, mainly from retrospective
medical claims databases, suggest that treatment persis-
tence with mirabegron may be greater than for antimus-
carinics in OAB [15–17].
The objective of this study was to compare treatment
persistence and adherence for mirabegron compared to
tolterodine extended-release (ER) over a 12-mo period,
consistent with a previous long-term comparative study
[18], and with other antimuscarinics in UK clinical practice.
Our study was based on prescription records from a large
primary and secondary care database in the UK, Clinical
Practice Research Datalink (CPRD). One other UK-specific
comparative study of persistence for mirabegron versus
antimuscarinics is ongoing, but has only been presented in
preliminary form to date [19,20]. As well as evaluating
persistence in the total study population, we also looked at
specific predefined subgroups of interest (ie, treatment-
naı¨ve, treatment experienced and elderly patients) and
applied matching to control for key baseline characteristics.
2. Patients and methods
2.1. Study design and data source
This was a retrospective, longitudinal, observational, cohort study of
patients who received a prescription for a target OAB medication in UK
clinical practice. The primary objective was to compare persistence on
treatment between mirabegron and tolterodine ER. Secondary objectives
included comparing persistence and adherence between mirabegron
and other antimuscarinics, and to describe patient characteristics that
affected persistence and adherence.Please cite this article in press as: Chapple CR, et al. Persistence and
Patients with Overactive Bladder: A Retrospective Observational S
10.1016/j.eururo.2017.01.037Anonymised data were taken from the CPRD GOLD, a large, nationally
representative, primary care research database that collates medical
records from 674 general practices across the UK. It includes data for
approximately 4.4 million active patients (ie, alive, currently registered)
who meet database quality criteria [21].
Approval for the study protocol was obtained from the CPRD
Independent Scientiﬁc Advisory Committee (protocol 16_097R; approv-
al date July 6, 2016). The study was conducted in compliance with
national and European Union requirements ensuring the rights of
participants in noninterventional studies.
2.2. Study population
Adults aged 18 yr with at least one prescription for a target drug issued
between May 1, 2013 and June 29, 2014 (selection period) were eligible
(Supplementary Fig. 1). The selection period was based on the
availability of mirabegron (approved in Europe in January 2013) and
to allow at least 12-mo patient follow-up before analysis of the database.
The target drugs were mirabegron, darifenacin, fesoterodine, ﬂavoxate,
oxybutynin ER or immediate-release (IR), propiverine, solifenacin,
tolterodine ER or IR, and trospium chloride. The ﬁrst prescription date
for a target drug initiated during the selection period was deﬁned as the
index date, and the drug was designated the index drug. Only patients
with a new prescription were included; patients with a prescription for
the index drug in the 12 mo before the index date were excluded.
Patients were required to have at least 12 mo of continuous enrolment in
CPRD before (pre-index period) and after (post-index period) the index
date. Prescriptions for combination therapy with two target drugs at the
index date or a 5a-reductase inhibitor (suggestive of benign prostatic
hyperplasia due to an enlarged prostate) during follow-up were not
permitted.
2.3. Endpoints
Persistence on treatment was assessed using two endpoints: median
time to discontinuation (primary endpoint) and the persistence rate at
12 mo. Adherence was also assessed using two endpoints: medication
possession ratio (MPR) at 12 mo and adherence rate at 12 mo. Deﬁnitions
of the endpoints are provided in Supplementary Table 1.
2.4. Statistical analysis
Analyses included all patients meeting the inclusion criteria. Analyses
were also stratiﬁed according to the following prespeciﬁed subcohorts at
index date: treatment-naı¨ve (no prescription for any target drug during
the pre-index period); treatment-experienced (prescription for at least
one non-index target drug during the pre-index period); and elderly
patients (65 yr).
Time to discontinuation was calculated using Kaplan-Meier survival
analysis, and differences between cohorts were assessed via log-rank
test; hazard ratios (HRs) are reported for comparisons between
mirabegron (reference) and antimuscarinics. Patients were censored if
they reached the end of follow-up without discontinuation. Cox
proportional-hazards regression models, adjusted for potential con-
founding factors (gender, age, Charlson index, treatment status,
hypertension, polypharmacy), were used to compare cohorts (expressed
as HR and 95% conﬁdence interval [CI]). For the primary analysis, OAB
treatment was deﬁned as discontinued if the maximum allowable gap
duration (MAGD) was at least 1.5 times the intended duration of the
most recent prescription. Sensitivity analyses were conducted using a
MAGD ratio of 2 and ﬁxed deﬁnitions of 30, 45, 60, and 90 d. Logistic
regression models, adjusted for potential confounding factors, were used
to compare 12-mo persistence rates between cohorts (expressed as odds
ratio [OR] and 95% CI). Proportions of persistent and adherent patients Adherence with Mirabegron versus Antimuscarinic Agents in
tudy in UK Clinical Practice. Eur Urol (2017), http://dx.doi.org/
Table 1 – Baseline characteristics
Characteristic Mirabegron
(n = 1203)
Tolterodine
ER (n = 1561)
Darifenacin
(n = 126)
Fesoterodine
(n = 1287)
Flavoxate
(n = 144)
Oxybutynin
ER (n = 1144)
Oxybutynin
IR (n = 5779)
Propiverine
(n = 95)
Solifenacin
(n = 8191)
Tolterodine
IR (n = 1523)
Trospium
chloride
(n = 943)
All patients
(N = 21 966)
Gender, n (%)
Male 293 (24) 563 (36)* 37 (29) 333 (26) 68 (47) 359 (31) 1748 (30) 22 (23) 2372 (29) 440 (29) 278 (29) 6513 (30)
Female 910 (76) 998 (64) 89 (71) 954 (74) 76 (53) 785 (69) 4031 (70) 73 (77) 5819 (71) 1083 (71) 665 (71) 15483 (70)
Age, years
Mean (SD) 64.1 (14.8) 64.6 (16.1) 63.5 (14.9) 63.3 (15.8) 64.6 (16.7) 61.6 (17.5) 63.4 (17.0) 66.3 (14.3) 63.8 (16.2) 66.4 (15.2) 66.3 (15.8) 63.94 (16.3)
Range 19.0–95.0 19.0–99.0 28.0–94.0 18.0–96.0 19.0–98.0 18.0–99.0 18.0–102.0 37.0–92.0 18.0–106.0 18.0–96.0 18.0–97.0 18.0–106.0
Age group, n (%)
<65 yr 542 (45) 685 (44) 60 (48) 623 (48) 68 (47) 596 (52) 2685 (46) 41 (43) 3816 (47) 615 (40) 372 (39) 10103 (46)
65 yr 661 (55) 876 (56) 66 (52) 664 (52) 76 (53) 548 (48) 3094 (54) 54 (57) 4375 (53) 908 (60) 571 (61) 11893 (54)
Treatment status, n (%)
Naı¨ve 476 (40) 1150 (74)* 73 (58) 799 (62) 111 (77) 907 (79) 5233 (91) 46 (48) 7021 (86) 990 (65) 549 (58) 17355 (79)
Experienced 727 (60) 411 (26) 53 (42) 488 (38) 33 (23) 237 (21) 546 (9.4) 49 (52) 1170 (14) 533 (35) 394 (42) 4641 (21)
CCI
Mean (SD) 0.38 (0.78) 0.35 (0.78) 0.41 (0.87) 0.40 (0.88) 0.47 (0.79) 0.36 (0.78) 0.38 (0.83) 0.44 (0.92) 0.38 (0.84) 0.36 (0.77) 0.38 (0.80) 0.38 (0.82)
Range 0.0–6.0 0.0–5.0 0.0–7.0 0.0–8.0 0.0–3.0 0.0–6.0 0.0–8.0 0.0–4.0 0.0–8.0 0.0–5.0 0.0–7.0 0.0–8.0
Hypertension, n (%)
No 1021 (85) 1316 (84) 111 (88) 1070 (83) 113 (78) 979 (86) 4865 (84) 74 (78) 6844 (84) 1270 (83) 795 (84) 18458 (84)
Yes 182 (15) 245 (16) 15 (12) 217 (17) 31 (22) 165 (14) 914 (16) 21 (22) 1347 (16) 253 (17) 148 (16) 3538 (16)
Polypharmacy, n (%)
0 113 (9.4) 172 (11)* 16 (13) 120 (9.3) 15 (10) 122 (11) 630 (11) 6 (6.3) 811 (9.9) 135 (8.9) 77 (8.2) 2217 (10)
1–3 329 (27) 515 (33) 36 (29) 424 (33) 28 (19) 365 (32) 1936 (34) 24 (25) 2680 (33) 484 (32) 259 (27) 7080 (32)
4–5 218 (18) 263 (17) 22 (17) 227 (18) 17 (12) 182 (16) 1055 (18) 15 (16) 1514 (18) 262 (17) 170 (18) 3945 (18)
6–8 245 (20) 321 (21) 29 (23) 253 (20) 34 (24) 215 (19) 1031 (18) 23 (24) 1612 (20) 291 (19) 213 (23) 4267 (19)
>8 298 (25) 290 (19) 23 (18) 263 (20) 50 (35) 260 (23) 1127 (20) 27 (28) 1574 (19) 351 (23) 224 (24) 4487 (20)
CCI = Charlson comorbidity index; ER = extended release; IR = immediate release; SD = standard deviation.
* p < 0.05 versus mirabegron.
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depending on the sample size.
Patients in the mirabegron cohort were randomly matched (1:1) to
patients in each of the other target drug cohorts based on sex, age (<65
or 65 yr), Charlson comorbidity index score [22,23], and treatment
status (naı¨ve or experienced) using a greedy algorithm. All analyses were
repeated in matched populations.
Analyses were performed using SAS version 9.4 (SAS Institute, Cary,
NC, USA).
3. Results
Between May 1, 2013 and June 29, 2014, 69 002 patients
with at least one prescription for a target OAB drug were
identified. A total of 47 006 (68%) patients were excluded
(Fig. 1), so 21 996 (32%) patients constituted the study
population. Solifenacin was the most commonly prescribed
drug (n = 8191, 37%), followed by oxybutynin IR (n = 5779,
26%). Other target drugs each accounted for less than 10% of
the study population, including mirabegron (5.5%). All
patients were followed for 12 mo.
Patient demographics and characteristics at baseline are
presented in Table 1. Compared to tolterodine ER, a
significantly higher proportion of patients prescribed
mirabegron were female (76% vs 64%), treatment-experi-
enced (60% vs 26%), and receiving more than eight
coexisting medications at the index date (25% vs 19%).Fig. 1 – Patient selection flowchart. 5-ARI = 5a reductase inhibitor; ER = extend
may have had more than one reason for exclusion.
Please cite this article in press as: Chapple CR, et al. Persistence and
Patients with Overactive Bladder: A Retrospective Observational S
10.1016/j.eururo.2017.01.0373.1. Mirabegron versus tolterodine ER
3.1.1. Unmatched analysis
Persistence was statistically significantly greater with
mirabegron than with tolterodine ER (Table 2). The median
time to discontinuation with mirabegron was 169 d (inter-
quartile range [IQR] 41–not reached) compared to 56 d (IQR,
28–254) with tolterodine ER (adjusted HR 1.55, 95% CI 1.41–
1.71; p < 0.0001; Fig. 2A). Persistence at 12 mo was also
significantly greater for mirabegron (38%) than for tolter-
odine ER (20%; adjusted OR 0.48, 95% CI 0.40–0.58;
p < 0.0001). Both persistence endpoints were significantly
greater with mirabegron than with tolterodine ER in all
predefined subcohorts (treatment-naı¨ve, treatment-experi-
enced, and 65 yr; p < 0.0001 for all comparisons; Table 2).
Mean MPR was significantly greater with mirabegron than
with tolterodine ER in all patients, and in the treatment-
naı¨ve and 65-yr-old subcohorts (p < 0.0001 all compar-
isons; Table 2).
Treatment discontinuation was significantly more likely
in treatment-naı¨ve patients (p < 0.0001), whereas age, sex,
comorbidities, hypertension, and coexistent medications
did not affect persistence (Table 3).
3.1.2. Matched analysis
Matched patient baseline characteristics are presented in
Supplementary Table 2. Time to discontinuation and 12-moed release; IR = immediate release; OAB = overactive bladder. *Patients
 Adherence with Mirabegron versus Antimuscarinic Agents in
tudy in UK Clinical Practice. Eur Urol (2017), http://dx.doi.org/
Table 2 – Persistence and adherence: mirabegron versus tolterodine ER (unmatched analysis)
Variable All patients Treatment-naı¨ve patients Treatment-experienced patients Elderly patients
Mirabegron
(n = 1203)
Tolterodine
ER (n = 1561)
Mirabegron
(n = 476)
Tolterodine
ER (n = 1150)
Mirabegron
(n = 411)
Tolterodine
ER (n = 727)
Mirabegron
(n = 661)
Tolterodine
ER (n = 876)
Persistence
Time to discontinuation (d)
Median (IQR) 169 (41–NR) 56 (28–254) 132 (30–NR) 56 (28–168) 189 (56–NR) 120 (28–581) 202 (52–NR) 56 (28–264)
Hazard ratio (95% CI)a 1.55 (1.41–1.71) 1.66 (1.46–1.88) 1.41 (1.21–1.63) 1.70 (1.50–1.94)
p value <0.0001 <0.0001 <0.0001 <0.0001
12-mo persistence, n (%) 454 (38) 318 (20) 164 (34) 192 (17) 290 (40) 126 (31) 274 (41) 184 (21)
Difference, % (95% CI) 17 (14–21) 18 (13–23) 9 (4–15) 20 (16–25)
Odds ratio (95% CI)a 0.48 (0.40–0.58) 0.39 (0.30–0.50) 0.62 (0.48–0.81) 0.41 (0.32–0.52)
p value <0.0001 <0.0001 <0.0001 <0.0001
Adherence
Patients (n) 955 889 345 609 610 280 540 500
MPR
Mean (SD)b 0.59 (0.33) 0.51 (0.33) 0.59 (0.33) 0.48 (0.33) 0.59 (0.34) 0.60 (0.31) 0.61 (0.33) 0.53 (0.33)
p value <0.0001 <0.0001 0.98 <0.0001
Adherent patients, c n (%) 410 (43) 290 (33) 150 (43) 177 (29) 260 (43) 113 (40) 252 (47) 176 (35)
Difference, % (95% CI) 10 (6–15) 14 (8–21) 2 (-5–9) 12 (5–17)
p value <0.0001 <0.0001 0.52 0.0002
Median follow-up (d) d 525 548 500 531 546 571 515 548
CI = conﬁdence interval; ER = extended release; IQR = interquartile range; MPR = medication possession ratio; NR = not reached; SD = standard deviation.
a Adjusted for gender, age group, treatment status, Charlson comorbidity index, hypertension, and polypharmacy at index date.
b MPRs ranged from 0 (no adherence) to 1 (perfect adherence).
c Patients considered to be adherent when MPR  0.8.
d Patients who did not discontinue treatment 12 mo after initiation.
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Fig. 2 – Time to discontinuation for mirabegron versus (A) tolterodine ER and (B) other antimuscarinics. ER = extended release; IR = immediate release.
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EURURO-7231; No. of Pages 11persistence were statistically significantly greater with
mirabegron than with tolterodine ER in all patients, as well
as in all three predefined subcohorts (p < 0.0001 all compar-
isons; Supplementary Table 3). Mean MPR was significantly
higher with mirabegron than with tolterodine ER in all
patients (0.60 vs 0.55; p = 0.03), and in the treatment-naı¨ve
subcohort (0.59 vs 0.49; p = 0.004; Supplementary Table 3).
3.1.3. Sensitivity analysis
Sensitivity analyses around the MAGD yielded findings
similar to the base-case analysis (Supplementary Table 4).
3.2. Mirabegron versus other antimuscarinics
3.2.1. Unmatched analysis
Persistence was statistically significantly better with
mirabegron than with each of the other antimuscarinics
(Table 4). The median time to discontinuation was
significantly longer with mirabegron (169 d) than with
other antimuscarinics (range 30–78 d), with the adjustedPlease cite this article in press as: Chapple CR, et al. Persistence and
Patients with Overactive Bladder: A Retrospective Observational S
10.1016/j.eururo.2017.01.037HR ranging from 1.24 to 2.26 (p < 0.0001 all comparisons;
Fig. 2B). Persistence at 12 mo was also significantly
greater with mirabegron (38%) than with other anti-
muscarinics (range 8.3–25%; p < 0.0001 for all agents,
except p = 0.002 for oxybutynin IR). Mirabegron statisti-
cally significantly increased both persistence endpoints
compared to each of the other antimuscarinics in all
predefined subcohorts, with the exception of propiverine
in treatment-experienced patients (Supplementary
Tables 5–13). The mean MPR was statistically significant-
ly greater with mirabegron (0.59) than with other
antimuscarinics in all patients (range 0.41–0.53; p values
0.01 to <0.0001; Table 4) and in treatment-naı¨ve patients
(range 0.39–0.51; p values 0.02 to <0.0001; Supplemen-
tary Tables 5–13).
Treatment discontinuation was significantly more likely
in women (p = 0.0075), in patients with more comorbidities
(p = 0.0006), patients aged <65 yr (p < 0.0001), treatment-
naive patients (p < 0.0001), and patients receiving two or
more other medications (Table 3). Adherence with Mirabegron versus Antimuscarinic Agents in
tudy in UK Clinical Practice. Eur Urol (2017), http://dx.doi.org/
Table 3 – Persistence (time to discontinuation): multivariate Cox regression model (unmatched analysis)
Covariates a HR (95% CI)b p value
Mirabegron versus tolterodine ER
Index drug Mirabegron (reference) – –
Tolterodine ER 1.55 (1.41–1.71) <0.0001
Gender Male (reference) – –
Female 0.96 (0.88–1.06) 0.44
Age in years <65 yr (reference) – –
65 yr 0.95 (0.87–1.04) 0.29
CCI score 0.95 (0.90–1.01) 0.09
Treatment status Naı¨ve (reference) – –
Experienced 0.74 (0.68–0.82) <0.0001
Hypertension No (reference) – –
Yes 0.90 (0.80–1.02) 0.10
Polypharmacy a 0 (reference) – –
1 0.98 (0.89–1.08) 0.67
2 0.78 (0.61–0.98) 0.04
3 0.66 (0.48–0.90) 0.01
4 0.88 (0.61–1.27) 0.49
Mirabegron versus antimuscarinics
Index drug Mirabegron (reference) – –
Darifenacin 1.77 (1.45–2.16) <0.0001
Fesoterodine 1.38 (1.26–1.51) <0.0001
Flavoxate 2.27 (1.89–2.72) <0.0001
Oxybutynin ER 1.46 (1.33–1.60) <0.0001
Oxybutynin IR 1.90 (1.76–2.05) <0.0001
Propiverine 1.66 (1.31–2.10) <0.0001
Solifenacin 1.24 (1.15–1.34) <0.0001
Tolterodine IR 1.59 (1.46–1.74) <0.0001
Trospium chloride 1.58 (1.43–1.74) <0.0001
Gender Male (reference) – –
Female 1.05 (0.90–1.16) 0.0075
Age <65 years (reference) – –
65 years 0.94 (0.86–1.09) <0.0001
CCI score 0.97 (0.89–1.03) 0.0006
Treatment status Naı¨ve (reference) – –
Experienced 0.69 (0.67–0.72) <0.0001
Hypertension No (reference) – –
Yes 0.92 (0.89–0.96) 0.15
Polypharmacy b 0 (reference) – –
1 1.03 (0.10–1.06) 0.0643
2 0.87 (0.80–0.94) 0.0003
3 0.81 (0.74–0.89) <0.0001
4 0.79 (0.69–0.89) 0.0004
CCI = Charlson comorbidity index; CI = conﬁdence interval; ER = extended release; HR = hazard ratio; IR = immediate release.
a HRs compared with reference variables for each covariate; HR > 1 indicates an increased likelihood of discontinuation with the test variable versus the
reference variable.
b Number of unique prescription drugs at the index date.
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Matching was successful for seven of the nine comparator
antimuscarinics; propiverine and darifenacin were not
considered because of small sample sizes. Persistence and
adherence outcomes for the matched comparisons are
presented in Supplementary Tables 6–9 and 11–13.
The median time to discontinuation (adjusted HR range
1.31–2.31; p < 0.0001 all comparisons) and 12-mo persis-
tence rates (adjusted OR range 0.18–0.71; p  0.0001 all
comparisons) were statistically significantly greater with
mirabegron than with other antimuscarinics in all patients.
An increase in both persistence endpoints was also evident
for mirabegron compared to other antimuscarinics in the
three predefined patient subcohorts (p values 0.04 to
<0.0001), except for 12-mo persistence versus solifenacin
in matched analysis of treatment-experienced patients. ThePlease cite this article in press as: Chapple CR, et al. Persistence and
Patients with Overactive Bladder: A Retrospective Observational S
10.1016/j.eururo.2017.01.037mean MPR was significantly greater with mirabegron than
with other antimuscarinics, except for solifenacin, in all
patients (p values 0.03 to <0.0001), and in treatment-naı¨ve
subcohorts, except for flavoxate (p values 0.02 to <0.0001).
4. Discussion
In this study, patients prescribed mirabegron were signifi-
cantly more likely to continue treatment in the long term
compared to those prescribed tolterodine ER, with 12-mo
persistence rates of 38% and 20% and median times to
discontinuation of 169 and 56 d, respectively. Persistence
was also significantly greater with mirabegron than with
each of the other comparator antimuscarinics, including the
two most commonly prescribed antimuscarinic agents in
this large UK population, oxybutynin IR and solifenacin. Adherence with Mirabegron versus Antimuscarinic Agents in
tudy in UK Clinical Practice. Eur Urol (2017), http://dx.doi.org/
Table 4 – Persistence and adherence: mirabegron versus antimuscarinic agents other than tolterodine ER in all patients (unmatched analysis)
Variable Mirabegron
(n = 1203)
Darifenacin
(n = 126)
Fesoterodine
(n = 1287)
Flavoxate
(n = 144)
Oxybutynin
ER (n = 1144)
Oxybutynin
IR (n = 5779)
Propiverine
(n = 95)
Solifenacin
(n = 8191)
Tolterodine
IR (n = 1523)
Trospium
chloride
(n = 943)
Persistence
Time to discontinuation (d)
Median (IQR) 169 (41–NR) 56 (28–179) 78 (28–353) 30 (30–64) 60 (30–208) 35 (28–108) 56 (28–258) 67 (30–366) 56 (28–285) 60 (28–237)
Hazard ratio (95% CI) a – 1.76 (1.44–2 .15) 1.37 (1.25–1.51) 2.26 (1.88–2.71) 1.46 (1.32–1.60) 1.90 (1.76–2.05) 1.66 (1.31–2.09) 1.24 (1.15–1.34) 1.59 (1.45–1.74) 1.57 (1.43–1.74)
p value – <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
12-mo persistence, n (%) 454 (38) 20 (16) 309 (24) 12 (8.3) 197 (17) 719 (12) 20 (21) 2028 (25) 313 (21) 180 (19)
Difference, % (95% CI) – 22 (15–29) 14 (10–17) 30 (24–35) 21 (17–24) 25 (23–28) 17 (8–25) 13 (10–16) 17 (14–21) 19 (15–22)
Odds ratio (95% CI)a – 0.35 (0.21–0.57) 0.60 (0.50–0.72) 0.19 (0.10–0.34) 0.45 (0.37–0.54) 0.33 (0.28–0.38) 0.45 (0.27–0.75) 0.74 (0.65–0.85) 0.48 (0.40–0.57) 0.42 (0.34–0.51)
p value – <0.0001 <0.0001 <0.0001 <0.0001 0.002 <0.0001 <0.0001 <0.0001 <0.0001
Adherence
Patients (n) 955 73 822 46 651 2775 55 5208 909 591
MPR
Mean (SD)b 0.59 (0.33) 0.46 (0.34) 0.53 (0.33) 0.44 (0.32) 0.49 (0.32) 0.41 (0.32) 0.51 (0.32) 0.53 (0.34) 0.50 (0.34) 0.48 (0.33)
p value – 0.002 0.001 0.004 <0.0001 <0.0001 0.07 <0.0001 <0.0001 <0.0001
Adherent patients,c n (%) 410 (43) 21 (29) 286 (35) 11 (24) 202 (31) 621 (22) 14 (25) 1846 (35) 291 (32) 169 (29)
Difference, % (95% CI) – 14 (3–25) 8 (4–13) 19 (6–32) 12 (7–17) 21 (17–24) 18 (6–30) 8 (4–11) 11 (7–15) 14 (10–19)
p value – 0.02 0.0005 0.01 <0.0001 <0.0001 0.01 <0.0001 <0.0001 <0.0001
Median follow-up (d) d 525 514 551 627 559 548 575 562 533 562
CI = conﬁdence interval; ER = extended release; IQR = interquartile range; IR = immediate release; MPR = medication possession ratio; NR = not reached; SD = standard deviation.
a Adjusted for gender, age group, treatment status, Charlson comorbidity index, hypertension, and polypharmacy at the index date.
b MPRs ranged from 0 (no adherence) to 1 (perfect adherence).
c Patients considered to be adherent when MPR 0.8.
d Patients who did not discontinue treatment 12 mo after initiation.
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defined subcohorts of treatment-naı¨ve, treatment-experi-
enced, and older patients, as well as after matching to
controls for potentially confounding differences in baseline
characteristics. The findings of a sensitivity analysis that
tested assumptions around the date of discontinuation
were similar to those of the base-case analysis. Adherence,
assessed in terms of MPR with a fixed denominator, was
significantly greater with mirabegron than with all anti-
muscarinics in the overall study population, although these
benefits appeared to be limited mainly to treatment-naı¨ve
patients in both matched and unmatched analyses. Overall,
our findings suggest that persistence and adherence with
mirabegron are statistically superior to those with other
antimuscarinics in a large UK primary care population. The
clinical significance of increased adherence has been
highlighted recently in a prospective study showing that
women who adhered to OAB medication had significantly
greater improvements in urinary symptoms than non-
adherent women did [24].
Our observations are consistent with other recent real-
world studies comparing mirabegron to antimuscarinic
agents under different health care systems in the US, Japan,
and Canada, which reported significantly better persistence
with mirabegron [15–17]. In the North American studies,
both of which were based on retrospective claims data, the
relative risk of discontinuation with mirabegron versus
tolterodine ER was similar to the present study (HR: Canada,
1.44; USA, 1.64; UK, 1.56) [15,16]. Persistence with
mirabegron versus tolterodine was also greater in treat-
ment-naive and treatment-experienced cohorts in both
studies [15,16], as in the present study. The smaller
Japanese study, based on medical records, reported a
significantly improved 12-mo persistence rate with mir-
abegron compared to tolterodine (38% vs 20%) [17], as in the
present study (38% vs 20%). In addition, two noncompara-
tive studies of persistence with mirabegron in UK popula-
tions have recently been reported [25,26], but cannot be
directly compared with our study because of a shorter
duration of follow-up in one study (6 mo) [25] and many
patients (37%) received mirabegron in combination with
antimuscarinics in the other [26].
In our study, discontinuation of antimuscarinics was less
common among men than among women and generally
occurred within 1–3 mo, compared to a median of 5.6 mo
with mirabegron. We were unable to examine the reasons
for discontinuation in our study as these data are not
contained within the CPRD database. However, data from a
large US survey (>5000 respondents) suggested that the
most common reasons for discontinuation of antimuscari-
nics were treatment not working as expected, switching to a
new medication, coping without medication, and side
effects [27]. Other reasons described in the literature
included inadequate patient counselling resulting in
unrealistic patient expectations [28], cost [27,29,30],
unwillingness to take long-term treatment [27], and
proactive treatment holidays, all of which may have
occurred in our study. It is conceivable that the initial
separation of the Kaplan-Meier curves (Fig. 2) is attributablePlease cite this article in press as: Chapple CR, et al. Persistence and
Patients with Overactive Bladder: A Retrospective Observational S
10.1016/j.eururo.2017.01.037to differences between mirabegron and antimuscarinics in
the occurrence of bothersome anticholinergic side effects,
notably dry mouth, [9,10]. The time to onset of adverse
events with antimuscarinics is approximately 1 wk [31] and
fits with this early difference between groups. The gradient
of the curves was generally comparable after 3 mo,
suggesting that reasons for later discontinuations may
have been common to both drug classes. Further efforts are
needed to better understand the reasons for discontinua-
tion of OAB medications and how to support patients so that
they achieve long-term compliance.
This study has many design strengths including a large
population from the CPRD database that is broadly
representative of the UK general population [21] and the
use of matching to control for baseline imbalances, notably
the proportion of treatment-experienced patients, which
was greater in the mirabegron cohort at baseline. The
unmatched analysis was used as the primary analysis
because, after applying the stringent inclusion/exclusion
criteria, it was uncertain if there would be adequate patient
numbers for matching. The main study limitations are its
retrospective design and the use of prescription-event rather
than patient-derived data (eg, patient diaries) to estimate
outcomes. Although patients with <12-mo follow-up after
treatment initiation were excluded (n = 6078; Fig. 1) to
support the assessment of all study objectives and end-
points, these patients could have theoretically been included
in the analysis of time to discontinuation. The inability to
capture reasons for discontinuation of treatment, as well as
any potential health benefits resulting from increased
persistence in terms of symptom severity and health-related
quality of life (HRQoL), were other limitations of this study. It
should also be noted that there was variation in the
prescribing of mirabegron relative to tolterodine ER in the
early months of the study selection period (Supplementary
Fig. 2), possibly because of the UK launch of mirabegron
(February 2013) and the release of updated treatment
guidelines to include mirabegron [32]. The relatively later
availability of mirabegron and its positioning within UK
guidelines [32] may also have contributed to the higher
proportion of treatment-experienced patients in this group.
Analyses of health care resource use and associated costs
from the present study will be reported separately. Large
prospective observational studies of mirabegron are ongo-
ing in the USA (PERSPECTIVE; https://clinicaltrials.gov/ct2/
show/NCT02386072) and Europe (BELIEVE; https://
clinicaltrials.gov/ct2/show/NCT02320773), which include
persistence and HRQoL outcomes in a real-life setting. These
studies may help to better understand the benefits of
improved treatment persistence, reasons for discontinua-
tion, and why men in our study were less likely to
discontinue treatment than women.
5. Conclusions
Patients receiving mirabegron remain on treatment for
significantly longer and have significantly better 12-mo
persistence and adherence rates compared to tolterodine ER
and other antimuscarinics commonly prescribed for OAB in Adherence with Mirabegron versus Antimuscarinic Agents in
tudy in UK Clinical Practice. Eur Urol (2017), http://dx.doi.org/
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X10
EURURO-7231; No. of Pages 11the UK. Mirabegron provides an alternative treatment
option for OAB with the potential to increase treatment
persistence. This is an important consideration for clinicians
when managing chronic conditions, as well as for payers
when considering the economic implications of available
treatments for OAB.
Author contributions: Christopher R. Chapple had full access to all the
data in the study and takes responsibility for the integrity of the data and
the accuracy of the data analysis.
Study concept and design: Chapple, Nazir, Hakimi, Siddiqui, Wagg,
Guelfucci.
Acquisition of data: Nazir, Siddiqui, Guelfucci, Khemiri.
Analysis and interpretation of data: Chapple, Nazir, Hakimi, Fatoye,
Siddiqui, Wagg, Guelfucci, Khemiri, Bowditch.
Drafting of the manuscript: Chapple, Fatoye, Siddiqui, Wagg.
Critical revision of the manuscript for important intellectual content:
Chapple, Nazir, Hakimi, Fatoye, Siddiqui, Wagg, Guelfucci, Khemiri,
Bowditch.
Statistical analysis: Fatoye, Guelfucci, Khemiri.
Obtaining funding: Nazir.
Administrative, technical, or material support: Nazir, Bowditch.
Supervision: Chapple, Nazir.
Other: None.
Financial disclosures: Christopher R. Chapple certiﬁes that all conﬂicts of
interest, including speciﬁc ﬁnancial interests and relationships and
afﬁliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/afﬁliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents ﬁled, received, or pending), are the following: Christopher R.
Chapple declares a grant from Astellas; research study fees plus
nonﬁnancial support from Astellas and Allergan; speaker fees plus
nonﬁnancial support from Astellas, Allergan, and Boston; and consul-
tancy/advisory fees plus nonﬁnancial support from Astellas, Allergan,
Medtronic, and Pﬁzer. Jameel Nazir, Zalmai Hakimi, Sally Bowditch, and
Emad Siddiqui are employed by Astellas. Francis Fatoye declares a grant
from Astellas. Florent Guelfucci and Amine Khemiri are employed by
Creativ-Ceutical, which received a grant from Astellas. Adrian Wagg
declares speaker, research, and consultancy fees from Astellas, Pﬁzer,
SCA AB, and Duchesnay (Canada).
Funding/Support and role of the sponsor: The study was funded by
Astellas and designed and analysed by Astellas in collaboration with the
authors. Astellas had a role in the design and conduct of the study;
management, analysis, and interpretation of the data; and preparation,
review, and approval of the manuscript. Medical writing support,
provided by Harriet Lamb and Tyrone Daniel from Bioscript Medical, was
funded by Astellas Pharma Inc.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
eururo.2017.01.037.
References
[1] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminol-
ogy in lower urinary tract function: report from the standardisation
sub-committee of the International Continence Society. Urology
2003;61:37–49.Please cite this article in press as: Chapple CR, et al. Persistence and
Patients with Overactive Bladder: A Retrospective Observational S
10.1016/j.eururo.2017.01.037[2] Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of
urinary incontinence, overactive bladder, and other lower urinary
tract symptoms in ﬁve countries: results of the EPIC study. Eur Urol
2006;50:1306–14.
[3] National Institute for Health and Care Excellence. The management
of lower urinary tract symptoms in men: NICE guideline CG97.
London, UK: NICE; 2010 http://guidance.nice.org.uk/CG97
[4] National Institute for Health and Care Excellence. The management
of urinary incontinence in women: NICE guideline CG171. London,
UK: NICE; 2013 http://guidance.nice.org.uk/CG171
[5] Oefelein MG. Safety and tolerability proﬁles of anticholinergic
agents used for the treatment of overactive bladder. Drug Saf
2011;34:733–54.
[6] Khullar V, Amarenco G, Angulo JC, et al. Efﬁcacy and tolerability of
mirabegron, a b3-adrenoceptor agonist, in patients with overactive
bladder: results from a randomised European-Australian phase
3 trial. Eur Urol 2013;63:283–95.
[7] Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized,
double-blind, parallel-group, placebo-controlled, multicentre
study to assess the efﬁcacy and safety of the b3-adrenoceptor
agonist, mirabegron, in patients with symptoms of overactive
bladder. Urology 2013;82:313–20.
[8] Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase
III trial of mirabegron in patients with overactive bladder. J Urol
2013;189:1388–95.
[9] Nitti VW, Chapple CR, Walters C, et al. Safety and tolerability of the
b3-adrenoceptor agonist mirabegron, for the treatment of overac-
tive bladder: results of a prospective pooled analysis of three 12-
week randomised phase III trials and of a 1-year randomised phase
III trial. Int J Clin Pract 2014;68:972–85.
[10] Maman K, Aballea S, Nazir J, et al. Comparative efﬁcacy and safety of
medical treatments for the management of overactive bladder: a
systematic literature review and mixed treatment comparison. Eur
Urol 2014;65:755–65.
[11] Cramer JA, Roy A, Burrell A, et al. Medication compliance and
persistence: terminology and deﬁnitions. Value Health 2008;11:
44–7.
[12] Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence
and persistence across 6 chronic medication classes. J Manage Care
Pharm 2009;15:728–40.
[13] Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in
the treatment of overactive bladder syndrome with anticholinergic
therapy: a systematic review of the literature. Int J Clin Pract
2011;65:567–85.
[14] Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with pre-
scribed antimuscarinic therapy for overactive bladder: a UK expe-
rience. BJU Int 2012;110:1767–74.
[15] Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence
with the new b3 receptor agonist, mirabegron, versus antimuscari-
nics in overactive bladder: early experience in Canada. Can Urol
Assoc J 2015;9:343–50.
[16] Nitti VW, Rovner ES, Franks B, et al. Persistence with mirabegron
versus tolterodine in patients with overactive bladder. Am J Pharm
Beneﬁts 2016;8:e25–33.
[17] Ogihara K, Kaguyama H, Sakamoto H, et al. Persistence with mir-
abegron in patients with overactive bladder: a comparative study
of mirabegron and antimuscarinicsInternational Continence Socie-
ty (ICS); October 20–24, Rio de Janeiro, Brazil. Abstract 576; 2014.
[18] Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-
blind, active-controlled phase 3 study to assess 12-month safety
and efﬁcacy of mirabegron, a b3-adrenoceptor agonist, in overac-
tive bladder. Eur Urol 2013;63:296–305.
[19] Wagg A, Foley S, Peters J, Scrine L. Persistence with mirabegron, a b3
adrenoceptor agonist, versus antimuscarinics in patients with Adherence with Mirabegron versus Antimuscarinic Agents in
tudy in UK Clinical Practice. Eur Urol (2017), http://dx.doi.org/
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X 11
EURURO-7231; No. of Pages 11over-active bladder: early UK experienceEuropean Association of
Urology Meeting; March 20–24, Madrid, Spain. Abstract 267; 2015.
[20] Wagg A, Foley S, Peters J, et al. Persistence and adherence with
mirabegron versus antimuscarinics in overactive bladder: retro-
spective analysis of a UK general practice prescription database-
Ninth European Urogynaecological Association Annual Meeting;
November 3–5, Amsterdam, Netherlands; 2016.
[21] Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource proﬁle:
Clinical Practice Research Datalink (CPRD). Int J Epidemiol
2015;44:827–36.
[22] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis 1987;40:373–83.
[23] Khan NF, Perera R, Harper S, et al. Adaptation and validation of the
Charlson Index for Read/OXMIS coded databases. BMC Fam Pract
2010;11:1.
[24] Andy UU, Arya LA, Smith AL, et al. Is self-reported adherence
associated with clinical outcomes in women treated with anticho-
linergic medication for overactive bladder? Neurourol Urodyn
2016;35:738–42.
[25] Pindoria N, Malde S, Nowers J, et al. Persistence with mirabegron
therapy for overactive bladder: a real life experience. Neurourol
Urodyn. In press. http://dx.doi.org/10.1002/nau.22943.Please cite this article in press as: Chapple CR, et al. Persistence and
Patients with Overactive Bladder: A Retrospective Observational S
10.1016/j.eururo.2017.01.037[26] Duckett J, Balachandran A. Tolerability and persistence in a large,
prospective case series of women prescribed mirabegron. Int Uro-
gynecol J 2016;27:1163–7.
[27] Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for
discontinuing overactive bladder medication. BJU Int 2010;105:
1276–82.
[28] Tarn DM, Heritage J, Paterniti DA, et al. Physician communication
when prescribing new medications. Arch Intern Med 2006;166:
1855–62.
[29] Campbell UB, Stang P, Barron R. Survey assessment of continuation
of and satisfaction with pharmacological treatment for urinary
incontinence. Value Health 2008;11:726–32.
[30] Dmochowski RR, Newman DK. Impact of overactive bladder on
women in the United States: results of a national survey. Curr Med
Res Opin 2007;23:65–76.
[31] Rudy D, Cline K, Harris R, et al. Time to onset of improvement in
symptoms of overactive bladder using antimuscarinic treatment.
BJU Int 2006;97:540–6.
[32] National Institute for Health and Care Excellence. Mirabegron for
treating symptoms of overactive bladder. Technology appraisal
guidance TA290. London, UK: NICE; 2013,. www.nice.org.uk/
guidance/ta290 Adherence with Mirabegron versus Antimuscarinic Agents in
tudy in UK Clinical Practice. Eur Urol (2017), http://dx.doi.org/
